Compare CLBK & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLBK | ANIP |
|---|---|---|
| Founded | 1927 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2026 | 1999 |
| Metric | CLBK | ANIP |
|---|---|---|
| Price | $10.81 | $79.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 6.7M | 238.1K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $3.97 | $21.01 |
| Revenue Next Year | $11.43 | $17.59 |
| P/E Ratio | $83.69 | ★ $62.88 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $10.70 | $63.67 |
| 52 Week High | $25.83 | $99.50 |
| Indicator | CLBK | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 21.97 | 44.35 |
| Support Level | $10.70 | $76.87 |
| Resistance Level | $16.27 | $83.66 |
| Average True Range (ATR) | 0.56 | 2.22 |
| MACD | -0.81 | -0.04 |
| Stochastic Oscillator | 0.83 | 34.61 |
Columbia Financial Inc is a federally chartered savings bank that serves the financial needs of depositors and the local community as a customer service-focused institution. The company offers traditional financial services to businesses and consumers in its market areas. It attracts deposits from the general public and uses those funds to originate various loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family real estate loans, construction loans, home equity loans and advances, and other consumer loans. The company also offers title insurance through its wholly owned subsidiary and provides a broad range of insurance products, including personal and business lines of insurance, mainly to customers and New Jersey residents.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.